-
Br J Cancer: Bovine white blood cell extract ICRP induces the occurrence of immunogenic cell death in breast cancer cells and builds long-term anti-tumor memory
Time of Update: 2021-02-24
further studies showing that preventive vaccination of ICRP-KCC can prevent tumor formation in BALB/c mouse models and induce long-term anti-tumor memory, including the maturation of DC in the lymph nodes, the increase of CD8-T cells in the lymph nodes, the area of exosome blood and tumors, and the specific cells of lysotoxic tumors.
-
AstraZeneia's Imfinzi failed to improve the overall survival rate of patients with head and neck cancer
Time of Update: 2021-02-24
EAGLE Phase III trial evaluated patients with relapsed or metastatic head and neck squamous cell carcinoma (HNSCC) progression after treatment with platinum chemotherapy with Imfinzi monotherapy or Imfinzi combined tremelimumab, and showed that imfinzi monotherapy and imfinzi combined treatment withtreimumab did not improve OS compared to standard chemotherapy (SoC) regardless of patient PD-L1 levels.
-
NEJM: The role of Enfortumab vedotin in patients with advanced urethra skin cancer
Time of Update: 2021-02-24
researchers conducted a globally open Phase 3 clinical trial using enfortumab vedotin to treat patients with localized advanced or metastatic urethroid skin cancer who had previously received platinum-containing chemotherapy and used PD-1 or PD-L1 inhibitors.
-
ASCO GU 2021: ADC class drug Enfortumab Vedotin's treatment effect in urethra skin cancer is announced (EV-301 study)
Time of Update: 2021-02-24
study showed that EV was the first targeted drug to show OS benefits in patients treated for localized late-stage or metastatic urethra skin cancer compared to standard chemotherapy.
-
How can cancer patients eat scientifically and healthily during the Spring Festival? The Dietary Guidebook for Tumor Populations is available here
Time of Update: 2021-02-24
suggest that this group of people during the Spring Festival pay attention to a light diet, appropriate increase in high-quality protein intake, such as milk, lean meat, fish, animal liver, etc., to help raise white blood cells.
-
Key 2020 research papers that must be read in the field of urethra skin cancer
Time of Update: 2021-02-24
intervention group (59 cases) patients received fissromycin C 3 times a week in random groups for a total of 2 weeks (59 cases), control group with urethra bladder tumor excision (TURBT) and 6 doses of auxiliary drips per week (61 cases).
-
ASCO GU 2021: CtDNA testing can effectively determine Olaparib's effect on desopathic prostate cancer (PROfound study)
Time of Update: 2021-02-24
sensitivity analysis, excluding patients with PPP2R2A gene mutations, HR was 0.76 (95% CI:0.58-1.00), and the mid-OS in the Olapali and control groups was 17.4 months and 13.6 months, respectively.
-
ASCO GU 2021: THE HIF-2 alpha inhibitor Belzutifan is visible in advanced renal transparent cell carcinoma
Time of Update: 2021-02-24
study (NCT03634540) further explores the efficacy of Belzutifan in combining cabotinib with patients with advanced cCRCC who were treated for the first time (queue 1) or who had previously received immunotherapy and TKIs (queue 2).
-
Br J Cancer: Serum A fetal protein levels and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Remo reed monotherapy
Time of Update: 2021-02-24
results showed that baseline AFP levels were identified as a prognostic factor for continuous and di-distribution (≥400 vs .lt;400 ng/ml) trials, and were able to predict the survival benefits of patients treated with ramucirumab in the REACH trial.
-
BMJ | Relax! Data for 440,000 people in Asia: HPV vaccine safety report
Time of Update: 2021-02-24
, a national queue study from South Korea assessed the link between HPV vaccination and adverse events among 440,000 Adolescent Girls in Asia, adding important evidence to the safety of HPV vaccines for Asian populations.
-
Boston Immune has an exclusive option and license agreement with Baiji Shenzhou to develop new TNFR2 antibodies
Time of Update: 2021-02-24
the collaboration with Baiji Shenzhou is a powerful validation of the Boston Immune antibody platform and an opportunity to demonstrate the potential of BITR2101 as a single drug and in collaboration with the immuno-checkpoint inhibitor tislezumab." TNFR2 is a member of the TNF-subject super family, which is highly expressed in many tumor types and has been shown to promote tumor cell growth.
-
Half a million studies have shown that eating spicy food reduces the risk of cancer in the digestive tract
Time of Update: 2021-02-24
, researchers from Peking University used a large forward-looking queue in China to analyze in detail the relationship between spicy eating and the incidence of three major digestive tract cancers, namely esophageal, stomach and colorectal cancers.
-
Nature Biomedical Engineering: New nanoparticles can be targeted to treat tumors
Time of Update: 2021-02-24
Recently, a team of researchers from the Harold Simmons Comprehensive Cancer Center at Southwest Medical Institution in the United States synthesized a drug different from the first generation of STING activators, which can activate STING in the body using cGAMP, a natural small molecule activator of STING.
-
J Immunol: Proper regular exercise inhibits cell aging and tumor development
Time of Update: 2021-02-24
further, even mice with advanced liver tumors showed that proper regular exercise reduced liver inflammation levels and improved metabolism in older mice compared to sedentary conditions.
-
Nat Commun: Dual target polyamine synthesis and ingestion: a potential treatment strategy for diffuse endogenetic brain bridge glioma
Time of Update: 2021-02-24
studies have shown that DIPG cells can compensate for the inhibition of ODC1 by raising the expression of the polyamine transport protein SLC3A2.
-
ASCO GU 2021: The immunotherapy of prostate cancer has dawned
Time of Update: 2021-02-24
For mCRPC patients who had not previously been treated with chemotherapy but had received new endocrine therapy, the ORR of the two immuno combination chemotherapy studies varied slightly, while the PSA remission rate, rPFS, and OS were all comparable, and the side reactions were similar and controllable.
-
Lancet oncol: Should right colon cancer excision clean the central lymph nodes?
Time of Update: 2021-02-24
trial aims to compare the efficacy and safety of the treatment of patients with right half colon cancer with complete colon membrane excision (CME) and D2 separation during laparoscopic right half colonectomy.
-
Lancet Oncol: Phase 3 test | Prognostication of endoscopic surgery vs intensive radiotherapy treatment for patients with relapsed nasopharyngeal cancer
Time of Update: 2021-02-24
This is a multi-center, open-label, randomized phase 3 trial conducted in three hospitals in China, recruiting locally relapsed NPC patients aged 18-70 years to have endoscopic nasopharyngeal cancer excision (ENPG group) or IMRT (IMRT group).
-
Nat Commun: The absence of BCMA's double allegiant gene in patients with multiple myeloma causes the development of drug resistance in CAR-T therapy
Time of Update: 2021-02-24
Targeted BCMA (B-cell mature antigen) inlay antigen-subject (CAR) T-cell therapy has now shown far-reaching and long-lasting response effects in recurring refractic multiple myeloma (MM), the initial Phase I/II study showed that the therapy has an overall response rate of 73-100% and a full response rate of 31-69%.
-
Odivo assisted in the treatment of myocardial immersive urethrial skin cancer, which extended the disease-free survival of patients by nearly 2 times
Time of Update: 2021-02-24
On February 8, 2021, NYSE: BMY announced the results of a Phase III clinical study, CheckMate -274: Odivo (Navuliyu monoanti) The treatment of patients with high risk of recurrence of muscle-layer immersive urethroid cancer reached the main study endpoint in all random populations and PD-L1 expression ≥1% of patients, which significantly improved patient disease-free survival (DFS).
